The more the better? An appraisal of combination therapies for actinic keratosis
Actinic keratoses (AK) are common precancerous lesions of the skin. Numerous interventions exist for the treatment of AK, including lesion‐ and field‐directed approaches. In daily practice, different treatment modalities are often combined to maximize clearance rates. However, whether a combination...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 34; no. 4; pp. 727 - 732 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley
01.04.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Actinic keratoses (AK) are common precancerous lesions of the skin. Numerous interventions exist for the treatment of AK, including lesion‐ and field‐directed approaches. In daily practice, different treatment modalities are often combined to maximize clearance rates. However, whether a combination therapy is preferable to monotherapy in terms of efficacy and safety has been subject of intense debate. In this review, we summarize the current knowledge on the efficacy and safety of local combination therapies for the treatment of patients with AK. Combination approaches of cryosurgery followed by photodynamic therapy (PDT), laser‐assisted PDT, PDT in combination with topical interventions and microneedling‐assisted PDT have shown slightly better efficacy results with similar tolerability compared to the respective monotherapy. However, the individual usage of combination therapies should be checked on a case‐by‐case basis and take into account individual patient‐ and lesion‐specific aspects as more resources are needed and because the individual monotherapies are already highly effective. |
---|---|
Bibliography: | CB has been a member of advisory boards for Almirall Hermal, Biofrontera, Galderma, ISDIN and Leo Pharma. CB has received speaker′s honoraria by Almirall Hermal, Galderma and Leo Pharma. CB has received funding for clinical research by Leo Pharma. The remaining authors declare no conflict of interests. Funding sources Conflicts of Interest None declared. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
ISSN: | 0926-9959 1468-3083 1468-3083 |
DOI: | 10.1111/jdv.15998 |